Molecular Partners AG NASDAQ:MOLN

Molecular Partners AG stock price today

$3.6
-1.69
-32.08%
Financial Health
0
1
2
3
4
5
6
7
8
9

Molecular Partners AG stock price monthly change

-14.24%
month

Molecular Partners AG stock price quarterly change

-14.24%
quarter

Molecular Partners AG stock price yearly change

+22.40%
year

Molecular Partners AG key metrics

Market Cap
187.26M
Enterprise value
112.63M
P/E
1.51
EV/Sales
0.59
EV/EBITDA
0.93
Price/Sales
1.03
Price/Book
0.83
PEG ratio
N/A
EPS
-1.78
Revenue
6.72M
EBITDA
-57.19M
Income
-58.53M
Revenue Q/Q
-10.22%
Revenue Y/Y
-66.07%
Profit margin
62.17%
Oper. margin
61.52%
Gross margin
0%
EBIT margin
61.52%
EBITDA margin
-850.34%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Molecular Partners AG stock price history

Molecular Partners AG stock forecast

Molecular Partners AG financial statements

Molecular Partners AG (NASDAQ:MOLN): Profit margin
Jun 2023 415K -15.98M -3852.29%
Sep 2023 2.54M -11.43M -450.18%
Dec 2023 1.03M -19.78M -1916.67%
Mar 2024 2.73M -11.32M -413.62%
Molecular Partners AG (NASDAQ:MOLN): Analyst Estimates
2025 18.66M -61.78M -331.1%
2026 17.79M -81.00M -455.34%
2027 71.30M -63.87M -89.57%
2028 114.09M -45.17M -39.6%
  • Analysts Price target

  • Financials & Ratios estimates

Molecular Partners AG (NASDAQ:MOLN): Earnings per share (EPS)
2023-03-09 -0.324 -0.54
Molecular Partners AG (NASDAQ:MOLN): Debt to assets
Jun 2023 230493000 24.51M 10.64%
Sep 2023 218118000 21.90M 10.04%
Dec 2023 198352000 21.92M 11.05%
Mar 2024 185605000 17.06M 9.19%
Molecular Partners AG (NASDAQ:MOLN): Cash Flow
Jun 2023 -13.28M 4.03M -274K
Sep 2023 -13.19M 17.77M -298K
Dec 2023 -14.86M 18.33M -298K
Mar 2024 -15.78M 16.34M -300K

Molecular Partners AG alternative data

Molecular Partners AG (NASDAQ:MOLN): Employee count
Aug 2023 175
Sep 2023 168
Oct 2023 168
Nov 2023 175
Dec 2023 175
Jan 2024 175
Feb 2024 175
Mar 2024 167
Apr 2024 167
May 2024 167
Jun 2024 167
Jul 2024 167

Molecular Partners AG other data

Friday, 13 December 2024
zacks.com
Sunday, 8 December 2024
globenewswire.com
Thursday, 7 November 2024
globenewswire.com
Thursday, 31 October 2024
globenewswire.com
Friday, 25 October 2024
globenewswire.com
Tuesday, 22 October 2024
globenewswire.com
globenewswire.com
Friday, 4 October 2024
globenewswire.com
Friday, 27 September 2024
globenewswire.com
Monday, 26 August 2024
globenewswire.com
Wednesday, 7 August 2024
seekingalpha.com
Monday, 17 June 2024
globenewswire.com
Friday, 14 June 2024
globenewswire.com
Tuesday, 11 June 2024
globenewswire.com
Saturday, 1 June 2024
globenewswire.com
Thursday, 16 May 2024
globenewswire.com
Monday, 29 April 2024
globenewswire.com
Friday, 19 April 2024
globenewswire.com
Wednesday, 17 April 2024
globenewswire.com
Friday, 15 March 2024
Seeking Alpha
Friday, 1 March 2024
GlobeNewsWire
Thursday, 14 December 2023
GlobeNewsWire
Tuesday, 14 November 2023
GlobeNewsWire
Thursday, 2 November 2023
GlobeNewsWire
Tuesday, 27 June 2023
GlobeNewsWire
Monday, 19 June 2023
GlobeNewsWire
Thursday, 25 May 2023
GlobeNewsWire
Tuesday, 16 May 2023
GlobeNewsWire
Thursday, 20 April 2023
Seeking Alpha
Friday, 14 April 2023
GlobeNewsWire
  • What's the price of Molecular Partners AG stock today?

    One share of Molecular Partners AG stock can currently be purchased for approximately $3.6.

  • When is Molecular Partners AG's next earnings date?

    Unfortunately, Molecular Partners AG's (MOLN) next earnings date is currently unknown.

  • Does Molecular Partners AG pay dividends?

    No, Molecular Partners AG does not pay dividends.

  • How much money does Molecular Partners AG make?

    Molecular Partners AG has a market capitalization of 187.26M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 96.29% to 7.04M US dollars. Molecular Partners AG made a loss 61.98M US dollars in net income (profit) last year or -$0.54 on an earnings per share basis.

  • What is Molecular Partners AG's stock symbol?

    Molecular Partners AG is traded on the NASDAQ under the ticker symbol "MOLN".

  • What is Molecular Partners AG's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Molecular Partners AG?

    Shares of Molecular Partners AG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • How many employees does Molecular Partners AG have?

    As Jul 2024, Molecular Partners AG employs 167 workers.

  • When Molecular Partners AG went public?

    Molecular Partners AG is publicly traded company for more then 4 years since IPO on 16 Jun 2021.

  • What is Molecular Partners AG's official website?

    The official website for Molecular Partners AG is molecularpartners.com.

  • How can i contact Molecular Partners AG?

    Molecular Partners AG can be reached via phone at +41 44 755 77 00.

Molecular Partners AG company profile:

Molecular Partners AG

molecularpartners.com
Exchange:

NASDAQ

Full time employees:

167

Industry:

Biotechnology

Sector:

Healthcare

Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Wagistrasse 14
Schlieren, 8952

CIK: 0001745114
ISIN: US60853G1067
CUSIP: 60853G106